Joshua Roth

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Hutchinson Institute for Cancer Outcomes Research (HICOR)
Assistant Member, Appointed: 2014
 
University of Washington
Department of Pharmacy
Affiliate Assistant Professor, Appointed: 2014
Professional Headshot of Joshua Roth

Mailing Address

1100 Fairview Ave N
M3-B232
Seattle, Washington 98109

Contact

Phone: (206) 667-7867

jroth@fredhutch.org

Degrees

Graduate Certificate, User-Centered Design, Department of Human-Centered Design and Engineering, University of Washington, 2015
PhD, University of Washington, Department of Pharmacy, 2012
MHA, University of Washington, Department of Health Services, 2008
BS, Union College (Schenectady, NY), Department of Psychology, 2004

Research Interests

Dr. Roth is an Assistant Member with the Hutchinson Institute of Cancer Outcomes Research at the Fred Hutchinson Cancer Research Center specializing in comparative effectiveness research (CER) methods, including: observational study design, mathematical modeling, systematic review, and meta-analysis. His research interests involve the application of CER methods to evaluate the benefit-risk tradeoffs and value of pharmaceutical and diagnostic technologies in cancer, with specific focus on pharmacogenomic testing applications, cancer screening strategies, and alternative treatment options in lung, breast, and prostate cancer. Dr. Roth received his MHA from the University of Washington Department of Health Services and a PhD in Pharmaceutical Outcomes Research and Policy from the University of Washington.

Memberships

American Society of Clinical Oncology
International Association for the Study of Lung Cancer
International Society for Pharmacoeconomics Outcomes Research (ISPOR)
Society for Medical Decision Making

Honors and Awards

2016, American College of Radiology 2016 Gold-Merit Abstract Award. 2016 American College of Radiology Annual Meeting.“The Potential Clinical, Resource Use, and Fiscal Impacts of Lung-RADS to Inform Low-Dose CT Lung Cancer Screening in the United States”.
2016, International Society for Pharmacoeconomics and Outcomes Research Best Podium Presentation by a New Investigator. 2016 International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting.“The Potential Clinical, Resource Use, and Fiscal Impacts of Lung-RADS to Inform Low-Dose CT Lung Cancer Screening in the United States”.
2015, Ronald D. Mann Best Paper Prize, Honorable Mention. 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management.“Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting” Pharmacoepidemiology and Drug Safety. 2015;24(6):619-627.
2015, Award for Outstanding Paper by a Young Investigator, 37th Annual North American Meeting of the Society for Medical Decision Making
2015, Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
2013, Best New Investigator Poster Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
2012-2014, Ruth L. Kirschstein National Research Service Award (NRSA T32), National Institutes of Health
2010, Best Student Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
2010, University of Washington Pharmaceutical Outcomes Research & Policy Program Endowed Prize in Health Policy and Economics

Academic Service

2010-present, Modeling Good Research Practices Task Force, International Society of Pharmacoeconomic and Outcomes Research
2010-present, Oncology Outcomes Research Working Group, International Society of Pharmacoeconomic and Outcomes Research
2006-2010, University of Washington Institutional Review Board
2009-2010, Admissions Committee, University of Washington Pharmaceutical Outcomes Research and Policy Program

Editorial and Review

  • New England Journal of Medicine
  • Annals of Internal Medicine
  • JAMA
  • JAMA Oncology
  • Pharmacogenetics and Genomics
  • PLOS One
  • Value in Health
  • Public Health Genomics
  • Medical Decision Making
  • BMJ Open
  • PharmacoEconomics
  • Health Policy
  • Journal of Oncology Practice
  • Tumor Biology
  • Current Drug Safety
  • Drug Design, Development and Therapy
  • Expert Review of Anticancer Therapy
  • Cancer Chemotherapy and Pharmacology
  • Journal of Gastrointestinal Cancer
  • Lung Cancer
  • Journal of Comparative Effectiveness Research

Previous Positions

2012-2014, Research Fellow, Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research (HICOR)
2012-2014, Kirschstein NRSA T32 Fellow, Group Health Research Institute
2010-2012, Research Assistant, University of Washington, Department of Pharmacy, Grant Titled "Pharmacogenetics in Rural and Underserved Populations"
2010-2011, Research Assistant, University of Washington, Department of Pharmacy, Grant Titled “Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN)”
2008-2010, Research Assistant, University of Washington, Department of Pharmacy, Grant Titled "Risk-Benefit Framework for Genetic Testing"
2005-2008, Federal Regulatory Affairs Coordinator, Swedish Medical Center, Swedish Cancer Institut

Funding

 

CURRENT RESEARCH SUPPORT

National Cancer Institute (NCI)                                                           12/15/2015-12/31/2017
5P30 CA015704-40 (PI: Gilliland)                                                         
CCSG Pilot Award, Fred Hutchinson Cancer Research Center      

Medical Overuse Among Traditionally Underserved Patients: Adherence to ASTRO ‘Choosing Wisely’ Recommendations Among Medicare and Commercially Insured Cancer Patients

Objective: Evaluate the association between multilevel factors, including race/ethnicity, insurance type, and area of residence, and the use of unnecessary radiation therapy procedures

Role: Principal Investigator

*Note: No salary support was requested.

National Cancer Institute (NCI)                                                          03/01/2016-08/31/2017
Parent Study U10CA18088-S1400 (PI: Blanke/Ramsey)                                                          
Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in the SWOG 1400 (S1400) Clinical Trial

An Evaluation of Missed Opportunities for the Diagnosis of Ovarian Cancer and Factors Associated with the Receipt of Inadequate Advanced Ovarian Cancer Therapy.

Objective: 1) To evaluate SEER-Medicare linked records for medical diagnoses made prior to a diagnosis of advanced ovarian cancer and determine the use of diagnostic studies in such patients, and 2) To assess the medical care that patients receive in the 90 days after diagnosis to identify areas that would benefit from physician and patient education in an effort to improve patient outcomes.

Role: Co-Investigator (PI: S Ramsey)

Genentech                                                                                                 9/01/2016-12/31/2016
PI: Roth                                                                        
Health Insurance Coverage as a Barrier to Enrollment in Cancer Clinical Trials: A Prospective, Patient-Level Survey of a Cancer Cooperative Clinical Trials Group                                                                                                      
Phase I—Protocol, Statistical Analysis Plan, & Survey Development

The Protocol, Statistical Analysis Plan, & Survey Development that will take place during this first phase will contribute to the evaluation of the incidence of insurance coverage uncertainties, concerns, and/or denials as a barrier to cancer treatment clinical trial participation using a prospective, patient-level survey of patients who are screened for eligibility for SWOG Phase I-III treatment trials.

COMPLETED RESEARCH SUPPORT

Centers for Disease Control and Prevention (CDC)
National Office of Public Health Genomics(NOPHG)                             9/30/2008-9/29/2011
U18 GD000005 (PI: D Veenstra)                                                        
Risk-Benefit Framework for Genetic Tests

Objective: Develop and evaluate a quantitative risk-benefit framework for assessing the clinical utility of genetic tests.

Role: Graduate Student

Dr. Roth’s effort on this project took place from 10/01/2008 - 9/30/2010.

National Cancer Institute (NCI)                                                               9/29/2009-8/31/2011
RC2 CA148570 (PI: S Ramsey)                                                       
Center for comparative effectiveness research in cancer genomics – CANCERGEN

Objective: CANCERGEN will integrate expertise in decision modeling, database linkage, ethics, policy, and clinical trial design in order to leverage and build upon the existing strengths of the SWOG clinical trials network to facilitate the rapid design and implementation of prospective CER studies of pharmacogenomic technologies.

Role: Graduate Student

Dr. Roth’s effort on this project took place from 6/01/2010 - 10/31/2011.

National Institute of General Medical Science (NIGMS)                        7/15/2010-6/30/2016
U01 GM092676  (PI: K Thummel)                                                    
Pharmacogenomics in Rural and Underserved Populations

Objective: Evaluate the association in warfarin patients between VKORC1/CYP2C9/CYP4F2 genetic variation and major bleeding events in community populations in the Pacific Northwest, and explore the influence of care setting.

Role: Post-Doctoral Scholar

Dr. Roth’s effort on this project took place from 7/06/2010 - 8/30/2012.

National Heart Lung and Blood Institute (NHLBI)                               09/01/2011-8/31/2015
HHSN 268201100046C (PI: G Anderson)                                     
Women’s Health Initiative Coordinating Center

Objective: To maximize the knowledge gained from the WHI resource, to expand the WHI resource, and to provide a service infrastructure to support the WHI committee structure.

Role: Post-Doctoral Scholar

Dr. Roth’s effort on this project took place from 9/01/2012 - 8/31/2013.

National Cancer Institute (NCI)                                                                  8/8/2012-7/31/2016
U01 HL116291 (PI: S Ramsey)                                                    
BMT CTN 1101 Ancillary Cost-Effectiveness Analysis
Cost-Effectiveness Analysis to a Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies

Objective: To determine the incremental cost-effectiveness of using dUCB vs. haplo-BM as donor cell sources for reduced intensity conditioning (RIC) blood or bone marrow transplantation in patients with select hematological malignancies.

Role: Post-Doctoral Scholar

Dr. Roth’s effort on this project took place from 1/01/2013 - 1/1/2014.

Agency for Healthcare Research and Quality                                          8/1/2014-7/31/2016
K12 HS022982 (PI: S Sullivan)                                                            
Mentored Career Development Program in Patient-Centered Outcomes Research

Objective: To provide scholars with multidisciplinary training in patient-centered outcomes research

Role: K12 Scholar, Key Personnel

*Note: The terms of this K Award specified that the remaining 20% of effort must be funded by the institution and prohibited the receipt of funding from any other federal grant during the duration of the award.

Recent Publications

2017
2016
2015
2014
2013
2012
2011
2010

Coming Soon: New Profiles System!

In preparation for the launch of our new profiles system, we are freezing updates to these profiles. If you have any questions, please email library@fredhutch.org.

Researcher Profiles

 

Related Websites

 

Scientific Divisions